Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 30:11:39.
doi: 10.5334/tohm.641. eCollection 2021.

Rhabdomyolysis Associated with Severe Levodopa-Induced Dyskinesia in Parkinson's Disease: A Report of Two Cases and Literature Review

Yuvadee Pitakpatapee  1 , Jindapa Srikajon  1 , Tanita Sangpeamsook  1 , Prachaya Srivanitchapoom  1
Affiliations
Review

Rhabdomyolysis Associated with Severe Levodopa-Induced Dyskinesia in Parkinson's Disease: A Report of Two Cases and Literature Review

Yuvadee Pitakpatapee et al. Tremor Other Hyperkinet Mov (N Y). .

Abstract

Background: Rhabdomyolysis associated with levodopa-induced dyskinesia (Rhab-LID) is an extremely rare, life-threatening, but treatable condition in patients with Parkinson's disease (PD).

Case report: We reported two cases of Rhab-LID. The first case was a 64-year-old man presenting with severe generalized dyskinesia with elevated serum creatine kinase (CK) level. He was diagnosed with Rhab-LID owing to unpredictable gastric emptying time. The second case was a 61-year-old woman presenting with fever, myalgia, and disabling dyskinesia with elevated serum CK. She was diagnosed with dyskinesia-hyperpyrexia syndrome (DHS) due to increasing dosage of ropinirole and infection. Dopaminergic medications were stopped, and supportive care was initiated in both cases with excellent outcomes.

Conclusion: Early recognition, stopping dopaminergic medications, treating precipitating causes, and proper supportive treatment can provide favorable outcomes.

Keywords: Dyskinesia; Dyskinesia hyperpyrexia; Hyperkinetic emergencies; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

References

    1. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010; 9(11): 1106–17. DOI: 10.1016/S1474-4422(10)70218-0 - DOI - PubMed
    1. Pandey S, Srivanitchapoom P. Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management. Ann Indian Acad Neurol. 2017; 20(3): 190–8. - PMC - PubMed
    1. Bektas H, Deniz O, Temel S, Keklikoglu HD, Akyol S. Rhabdomyolysis related to dyskinesia in Parkinson’s disease. J Mov Disord. 2014; 7(1): 25–7. DOI: 10.14802/jmd.14006 - DOI - PMC - PubMed
    1. Sarchioto M, Ricchi V, Melis M, Deriu M, Arca R, Melis M, et al. Dyskinesia-Hyperpyrexia Syndrome in Parkinson’s Disease: A Heat Shock-Related Emergency? Mov Disord Clin Pract. 2018; 5(5): 534–7. DOI: 10.1002/mdc3.12663 - DOI - PMC - PubMed
    1. Novelli A, Di Vico IA, Terenzi F, Sorbi S, Ramat S. Dyskinesia-Hyperpyrexia Syndrome in Parkinson’s disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone. Parkinsonism Relat Disord. 2019; 64: 352–3. DOI: 10.1016/j.parkreldis.2019.05.018 - DOI - PubMed